Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma.

PURPOSE Valosin-containing protein (VCP; also known as p97) was shown to be associated with antiapoptotic function and metastasis via activation of nuclear factor kappa-B signaling pathway. In this study, association of VCP expression with recurrence of gastric carcinoma (GC), in which lymphatic vessels are the main route of spread, was examined. PATIENTS AND METHODS VCP expression in 330 patients with GC (242 males and 88 females) with ages ranging from 26 to 81 years (median, 60 years) was analyzed by immunohistochemistry, in which staining intensity in tumor cells was categorized as weaker (level 1) or equal to or stronger (level 2) than that in endothelial cells. RESULTS Ninety-four (28.7%) patient cases showed level 1 and 233 patient cases (71.3%) showed level 2 VCP expression. Patients with level 2 expression showed higher rates of large tumor size (P <.0001), undifferentiated histologic subtype (P <.05), presence of vascular and lymphatic invasion (P <.0001 for both), presence of lymph node metastasis (P <.0001), deep tumor invasion (P <.0001), and poorer disease-free and overall survivals (P <.0001 for both) compared with those with level 1 VCP expression. Multivariate analysis revealed VCP expression level as an independent prognosticator for disease-free and overall survival. VCP level was an indicator for disease-free and overall survival in the early (pT1; P <.01 and P <.05, respectively) and advanced (pT2-4; P <.05 for both) group of pathologic tumor-node-metastasis system classification. CONCLUSION The prognostic significance of VCP expression level in GC was demonstrated.

[1]  M. Monden,et al.  Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Alitalo,et al.  Metastasis: Lymphangiogenesis and cancer metastasis , 2002, Nature Reviews Cancer.

[3]  A. Picciocchi,et al.  Impact of the latest TNM classification for gastric cancer: Retrospective analysis on 94 D2 gastrectomies , 2002, World Journal of Surgery.

[4]  H. Yoshikawa,et al.  VCP (p97) Regulates NFKB Signaling Pathway, Which Is Important for Metastasis of Osteosarcoma Cell Line , 2002, Japanese journal of cancer research : Gann.

[5]  Agathe Guilloux,et al.  Incidence and mortality from stomach cancer in Japan, Slovenia and the USA , 2002, International journal of cancer.

[6]  M. Tsuneyoshi,et al.  Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  G. Ranzani,et al.  Molecular mechanisms involved in the pathogenesis of gastric carcinoma: interactions between genetic alterations, cellular phenotype and cancer histotype. , 2001, Hepato-gastroenterology.

[8]  Y. Doki,et al.  Genetic detection of lymph node micrometastases in patients with gastric carcinoma by multiple‐marker reverse transcriptase‐polymerase chain reaction assay , 2001, Cancer.

[9]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[10]  A. Kakita,et al.  Recent results in the surgical treatment of gastric cancer according to the Japanese and TNM classification. , 2001, Anticancer Research.

[11]  G. Mann,et al.  Immunohistochemically detected micrometastases of the lymph nodes in patients with gastric carcinoma , 2001, Cancer.

[12]  S. Corsale,et al.  DNA aneuploidy and high proliferative activity but not K‐ras‐2 mutations as independent predictors of clinical outcome in operable gastric carcinoma , 2001, Cancer.

[13]  A. Baldwin Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. , 2001, The Journal of clinical investigation.

[14]  J. Puzas,et al.  Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. , 2000, Cancer research.

[15]  G. Stamp,et al.  The Mouse p97 (CDC48) Gene , 1999, The Journal of Biological Chemistry.

[16]  R. Seruca,et al.  The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. , 1998, The American journal of pathology.

[17]  D. Longo,et al.  Involvement of Valosin-containing Protein, an ATPase Co-purified with IκBα and 26 S Proteasome, in Ubiquitin-Proteasome-mediated Degradation of IκBα* , 1998, The Journal of Biological Chemistry.

[18]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[19]  B. Iacopetta,et al.  p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma , 1996, International journal of cancer.

[20]  Y. Maehara,et al.  Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. , 1996, Surgery.

[21]  M A Fujino,et al.  Gastric carcinoma, an endoscopically curable disease. , 1994, Bildgebung = Imaging.

[22]  T. Sano,et al.  Recurrence of early gastric cancer. Follow‐up of 1475 patients and review of the Japanese literature , 1993, Cancer.

[23]  D. Lane,et al.  p53 expression and prognosis in gastric carcinoma , 1992, International journal of cancer.

[24]  Y. Doki,et al.  Expression of immunoreactive E-cadherin adhesion molecules in human cancers. , 1991, The American journal of pathology.

[25]  J. Siewert,et al.  Surgical therapy for gastric cancer. , 1995, The Journal of infusional chemotherapy.

[26]  Brennan Mf,et al.  Progress in the management of gastric cancer. , 1994 .

[27]  D. Cox Regression Models and Life-Tables , 1972 .